Compare compounds

Vials

5 mg

Dosing data

Lab reference — not listed

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety. It is studied alone and combined with semaglutide (CagriSema).

• Phase 2 (26 weeks): every cagrilintide arm reduced weight more than placebo (6.0%–10.8% vs 3.0%); the top arm also beat liraglutide (10.8% vs 9.0%).
• REDEFINE 1 (3,417 adults without diabetes): cagrilintide–semaglutide gave −20.4% mean weight change at 68 weeks vs −3.0% with placebo.
• REDEFINE 2 (type 2 diabetes): −13.7% vs −3.4% with placebo at 68 weeks.

• Investigational: not approved as a standalone medicine.
• Phase 2: gastrointestinal events in 41%–63% vs 32% on placebo, mainly nausea. REDEFINE 1: gastrointestinal events in 79.6% vs 39.9%.

3 references · view